Buy Rating for Liquidia Technologies: Strategic Positioning and Market Undervaluation Present a Buying Opportunity

Needham analyst Serge Belanger maintained a Buy rating on Liquidia Technologies (LQDA – Research Report) today and set a price target of $32.00.

Serge Belanger has given his Buy rating due to a combination of factors that indicate a promising future for Liquidia Technologies. Despite recent competitive pressures from Insmed’s positive trial results for TPIP, Belanger believes that the market reaction has been overly negative towards Liquidia. The company’s own development of L606, a next-generation inhaled treprostinil product, is positioned to compete effectively as the market shifts towards therapies with more sustained-release profiles.
Belanger notes that Liquidia’s L606 program is expected to begin phase 3 development in late 2025, which aligns with the timeline for TPIP’s market entry. This strategic positioning, along with the potential for L606 to improve upon existing treatments that require more frequent dosing, supports the Buy rating. Belanger suggests that the current market undervaluation of Liquidia’s stock presents a buying opportunity as the company advances its competitive inhaled therapy offerings.

In another report released today, BTIG also reiterated a Buy rating on the stock with a $45.00 price target.